ArticleCell reports2017
Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 123 citations in OpenAlex.
- Subclinical Atherosclerosis, Hyperlipidemia and New-Onset Diabetes Should Not Be Ignored Despite Initial Angiographic Exclusion of Significant Atherosclerotic Occlusive Arterial Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Context-dependent regulation of endothelial inflammation and atherosclerosis by endothelial microRNA-33.Atherosclerosis · 2026Article
- Non-coding RNAs in lipid metabolism and their roles in atherosclerosis.Nature reviews. Cardiology · 2026Review
- Lipid-associated macrophages and metabolic inflammatory diseases.Cell insight · 2026Review
- MiR-7683-3p from M2-exosomes attenuated atherosclerosis by activating the PPARγ-LXRα-ABCG1 pathway mediated cholesterol efflux of vascular smooth muscle cell derived foam cells.Journal of nanobiotechnology · 2025Article
- Advances in the Regulation of Lipid Metabolism by Non-Coding RNAs.Animals : an open access journal from MDPI · 2025Review
- miR-33 inhibition as a novel therapeutic approach for treating muscular dystrophy.EMBO molecular medicine · 2025Article
- The power of microRNA regulation-insights into immunity and metabolism.FEBS letters · 2025Review
- Global Perspectives on Coronary Artery Disease: The Emerging Role of miRNAs.Current atherosclerosis reports · 2025Review
- Fusogenic Nanoreactor-Based Detection of Extracellular Vesicle-derived miRNAs for Diagnosing Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Exosomal non-coding RNAs: key regulators of inflammation-related cardiovascular disorders.European journal of medical research · 2025Review
- Sodium Danshensu Inhibits Macrophage Inflammation in Atherosclerosis via the miR-200a-3p/MEKK3/NF-κB Signaling Pathway.Molecular neurobiology · 2025Article
- A Novel Role for Coilin in Vertebrate Innate Immunity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Cellular Phenotypic Transformation During Atherosclerosis: The Potential Role of miRNAs as Biomarkers.International journal of molecular sciences · 2025Review
- Article
- Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.JCI insight · 2024Article
- Resveratrol suppresses hepatic fatty acid synthesis and increases fatty acid β-oxidation via the microRNA-33/SIRT6 signaling pathway.Experimental and therapeutic medicine · 2024Article
- LncRNA DANCR promotes macrophage lipid accumulation through modulation of membrane cholesterol transporters.Aging · 2024Article
- Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2024Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Nathan L PriceVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Noemi RotllanVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Alberto Canfrán-DuqueVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Xinbo ZhangVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Paramita PatiVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Noemi AriasEdward A. Doisy Department of Biochemistry and Molecular Biology and Center for Cardiovascular Research, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
Jack MoenVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Manuel MayrKing's British Heart Foundation Centre, King's College London, London WC2R 2LS, UK.
David A FordEdward A. Doisy Department of Biochemistry and Molecular Biology and Center for Cardiovascular Research, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
Ángel BaldánEdward A. Doisy Department of Biochemistry and Molecular Biology and Center for Cardiovascular Research, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
Yajaira SuárezVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Carlos Fernández-HernandoVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, and Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: carlos.fernandez@yale.edu.
Yale University · USSaint Louis University · USKing's College London · GB
Funding
Novel insights into the molecular and cellular mechanism regulating lipid metabolism and atherosclerosisR35HL135820 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2017 to 2023
$6.0MmicroRNAs in vascular diseasesR01HL105945 · NHLBI · YALE UNIVERSITY · PI SUAREZ, YAJAIRA · 2011 to 2020
$3.7MControl Sterol and Lipoprotein Homeostasis by miRNAR01HL107794 · NHLBI · SAINT LOUIS UNIVERSITY · PI BALDAN, ANGEL · 2011 to 2019
$3.3MCaveolin-1 in Lipoprotein Metabolism and Atherosclerosis.R01HL106063 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2011 to 2016
$2.5MRole of microRNAs in lipid metabolism and cardiovascular diseaseR01HL107953 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2011 to 2016
$2.4MHL-Regulation of Angiogenesis in the Obese Adipose Tissue by Secreted microRNAsR01HL135012 · NHLBI · YALE UNIVERSITY · PI SUAREZ, YAJAIRA · 2017 to 2020
$2.1MRole of miR-33b in the differentiation and function of white adipose tissueF32DK103489 · NIDDK · YALE UNIVERSITY · PI PRICE, NATHAN · 2014 to 2016
$177kBritish Heart Foundation CH/16/3/32406British Heart Foundation FS/13/2/29892British Heart Foundation RG/16/14/32397British Heart Foundation SP/12/5/29574NHLBI NIH HHS R01 HL105945NHLBI NIH HHS R01 HL106063NHLBI NIH HHS R01 HL107794NHLBI NIH HHS R01 HL107953NHLBI NIH HHS R01 HL135012NHLBI NIH HHS R35 HL135820NIDDK NIH HHS F32 DK103489
Abstract
As an important regulator of macrophage cholesterol efflux and HDL biogenesis, miR-33 is a promising target for treatment of atherosclerosis, and numerous studies demonstrate that inhibition of miR-33 increases HDL levels and reduces plaque burden. However, important questions remain about how miR-33 impacts atherogenesis, including whether this protection is primarily due to direct effects on plaque macrophages or regulation of lipid metabolism in the liver. We demonstrate that miR-33 deficiency in Ldlr
Indexed as
AnimalsAortaAtherosclerosisATP Binding Cassette Transporter 1Blood GlucoseCells, CulturedCholesterolCholesterol, HDLDisease ProgressionGene Regulatory NetworksMacrophages, PeritonealMaleMiceMice, Inbred C57BLMice, KnockoutMicroRNAsAbca1 protein, mouseATP Binding Cassette Transporter 1Blood GlucoseCholesterolCholesterol, HDLHadhb protein, mouseMicroRNAsMirn33 microRNA, mouseMitochondrial Trifunctional Protein, beta SubunitReceptors, LDLAtherosclerosischolesterolHDL-CmetabolismmiR-33
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.